Osteopontin regulates type I collagen fibril formation in bone tissue.

Osteopontin (OPN) is a non-collagenous protein involved in biomineralization of bone tissue. Beyond its role in biomineralization, we show that osteopontin is essential to the quality of collagen fibrils in bone. Transmission electron microscopy revealed that, in Opn-/- tissue, the organization of the collagen fibrils was highly heterogeneous, more disorganized than WT bone and comprised of regions of both organized and disorganized matrix with a reduced density. The Opn-/- bone tissue also exhibited regions in which the collagen had lost its characteristic fibrillar structure, and the crystals were disorganized. Using nanobeam electron diffraction, we show that damage to structural integrity of collagen fibrils in Opn-/- bone tissue and their organization causes mineral disorganization, which could ultimately affect its mechanical integrity. STATEMENT OF SIGNIFICANCE: This study presents new evidence about the role of osteopontin (OPN) - a non-collagenous protein - on the structure and organization of the organic and mineral matrix in bone. In previous work, osteopontin has been suggested to regulate the nucleation and growth of bone mineral crystals and to form sacrificial bonds between mineralized collagen fibrils to enhance bone's toughness. Our findings show that OPN plays a crucial role before mineralization, during the formation of the collagen fibrils. OPN-deficient bones present a lower collagen content compared to wild type bone and, at the tissue level, collagen fibrils organization can be significantly altered in the absence of OPN. Our results suggest that OPN is critical for the formation and/or remodeling of bone collagen matrix. Our findings could lead to the development of new therapeutic strategies of bone diseases affecting collagen formation and remodeling.

Fracture toughness of bone at the microscale.

Bone's hierarchical arrangement of collagen and mineral generates a confluence of toughening mechanisms acting at every length scale from the molecular to the macroscopic level. Molecular defects, disease, and age alter bone structure at different levels and diminish its fracture resistance. However, the inability to isolate and quantify the influence of specific features hampers our understanding and the development of new therapies. Here, we combine in situ micromechanical testing, transmission electron microscopy and phase-field modelling to quantify intrinsic deformation and toughening at the fibrillar level and unveil the critical role of fibril orientation on crack deflection. At this level dry bone is highly anisotropic, with fracture energies ranging between 5 and 30 J/m2 depending on the direction of crack propagation. These values are lower than previously calculated for dehydrated samples from large-scale tests. However, they still suggest a significant amount of energy dissipation. This approach provides a new tool to uncouple and quantify, from the bottom up, the roles played by the structural features and constituents of bone on fracture and how can they be affected by different pathologies. The methodology can be extended to support the rational development of new structural composites.